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Background: Bmi1 has been identified as an important regulator in breast cancer, but its relationship with other
signaling molecules such as ERα and HER2 is undetermined.
Methods: The expression of Bmi1 and its correlation with ERα, PR, Ki-67, HER2, p16INK4a, cyclin D1 and pRB was
evaluated by immunohistochemistry in a collection of 92 cases of breast cancer and statistically analyzed. Stimulation
of Bmi1 expression by ERα or 17β-estradiol (E2) was analyzed in cell lines including MCF-7, MDA-MB-231, ERα-restored
MDA-MB-231 and ERα-knockdown MCF-7 cells. Luciferase reporter and chromatin immunoprecipitation assays were
also performed.
Results: Immunostaining revealed strong correlation of Bmi1 and ERα expression status in breast cancer. Expression of
Bmi1 was stimulated by 17β-estradiol in ERα-positive MCF-7 cells but not in ERα-negative MDA-MB-231 cells, while the
expression of Bmi1 did not alter expression of ERα. As expected, stimulation of Bmi1 expression could also be achieved
in ERα-restored MDA-MB-231 cells, and at the same time depletion of ERα decreased expression of Bmi1. The proximal
promoter region of Bmi1 was transcriptionally activated with co-transfection of ERα in luciferase assays, and the
interaction of the Bmi1 promoter with ERα was confirmed by chromatin immunoprecipitation. Moreover, in
breast cancer tissues activation of the ERα-coupled Bmi1 pathway generally correlated with high levels of cyclin
D1, while loss of its activity resulted in aberrant expression of p16INK4a and a high Ki-67 index, which implied a
more aggressive phenotype of breast cancer.
Conclusions: Expression of Bmi1 is influenced by ERα, and the activity of the ERα-coupled Bmi1 signature
impacts p16INK4a and cyclin D1 status and thus correlates with the tumor molecular subtype and biologic behavior. This
demonstrates the important role which is played by ERα-coupled Bmi1 in human breast cancer.
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Breast cancer which is currently the most common ma-
lignant tumor in females worldwide, shows characteris-
tic heterogeneity that has a genetic or molecular basis.
Thus far at least five molecular subtypes of breast
cancer have been defined that include Luminal-A,
Luminal-B, Luminal-B-HER2, HER2-enriched and basal* Correspondence: zhangbo@bjmu.edu.cn
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reproduction in any medium, provided the orlike. Definition of these subtypes has allowed treatment
to be tailored directly for each type in breast cancer, and
marked progress has been made in improving patient
survival rate [1]. However, varying sensitivity to treat-
ment and resistance to endocrine or targeted therapy
which may be found de novo or may be acquired still
presents a therapeutic challenge. Much effort is still
needed to completely characterize all the molecular de-
tails which may be related to therapeutic targets in
breast cancer.
As a hormonally driven tumor, breast cancer is closely
associated with estrogen and its α receptor (ERα), intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Up to 70% of breast cancers show ERα expression, and
two-thirds of ERα-positive breast carcinoma patients
respond to treatment with anti-estrogen therapy [2-4],
while breast cancer lacking ERα expression does not
benefit from endocrine treatment. Nevertheless, many
patients with ERα positive cancer are unresponsive to
endocrine therapy, and all patients with advanced dis-
ease eventually develop resistance to the therapy [2,5].
ERα-associated signaling has therefore become a topic of
significant interest in the battle against breast cancer.
Like other steroid receptors, ERα can directly activate its
target genes such as PR and cyclin D1 through an inter-
active element (ERE, estrogen responsive element) [6].
In a recent study, ERα has been shown to cross talk with
other growth factor pathways (non-genomic activity) [6].
In addition to genetic and protein interaction, epigenetic
mechanisms of ERα regulation have also received atten-
tion in recent years. Silencing or reactivation of ERα by
epigenetic regulation has been demonstrated in cultured
breast cancer cells [7]. At the same time, the expression
of HOXB13 or CDK10 regulated by promoter methyla-
tion affects ERα status [8,9]. Moreover, epigenetic modi-
fication has been documented in breast cancer.
Bmi1 (Bmi1 polycomb ring finger oncogene) which
encodes a polycomb ring finger protein, was originally
cloned as a c-myc cooperating oncogene in murine lymph-
oma [10]. It has subsequently been identified as a tran-
scriptional repressor belonging to the polycomb group
(PcG) proteins, and is also a key factor in the polycomb re-
pressor complex 1 (PRC1), which serves as an important
epigenetic regulatory complex for modulation of chroma-
tin remodeling [11]. To date, many PRC1 target genes
have been identified including homeobox (HOX) genes
and p16INK4a, whose promoters contain interactive ele-
ments which bind directly to Bmi1 [12]. A striking finding
in recent studies is that the activity of Bmi1 is indispens-
able for cell survival and self-renewal of stem cells or can-
cer stem cells [13-15]. Over-expression of Bmi1 has been
found in a large number of human cancers, and a set of 11
genes which make up the Bmi1 signature has been defined
in colorectal, breast, lung and prostate cancers [16-18].
Bmi1 expression in breast cancer has also been found to
be associated with other tumor genes [19-21] and in vitro
models have demonstrated Bmi1 is required for metastasis
of breast cancer [22]. However, there has been no demon-
stration of any relationship of Bmi1 with other significant
factors in breast cancer such as ERα, PR, HER2 and Ki-67.
In this study, we at first identified a strong correlation of
ERα status with Bmil expression in a collection of breast
cancer tissues, and we then demonstrated the positive regu-
latory role ERα may play in transcriptional expression of
the Bmi1 gene. The ERα-coupled Bmi1 regulatory pathway
was subsequently evaluated with regard to its down-streamgenes such as p16INK4a and cyclin D1 and clinic-
pathological features in breast cancer. Results strongly
suggest the ERα-coupled Bmi1 regulatory pathway may be
one of the main regulatory mechanisms in breast cancer,
whose activity determines the down-stream gene status
of p16INK4a and cyclin D1, and consequently impacts the
biologic behavior of breast cancer.
Methods
Ethics statement
Paraffin-embedded archival breast cancer tissues were ob-
tained from the Pathology Department of Peking Uni-
versity Third Hospital. This study was conducted after
receiving approval from the Peking University Health Sci-
ence Center Institutional Review Board (IRB). Primary
tumor samples were all collected from archival tissues with
deletion of all patient identifiers from the retrospective
clinical data used in our study. Sample and data collection
were approved for informed consent waiver by the IRB.
Tissue specimens
Tumor samples were obtained from radical mastectomies
in 92 cases of invasive breast carcinoma confirmed by
histopathology in the Pathology Department of Peking
University Third Hospital. All cases were scored histologi-
cally as grade I, II and III, according to the Nottingham
grading criteria which includes extent of formation of
glandular lumina, nuclear atypia and the mitotic index.
The TNM classification classes T1 to T4 were used to
evaluate the tumor size (T1: ≤ 2 cm,T2: >2 cm but ≤ 5 cm,
T3: > 5 cm and T4: tumor of any size, with direct exten-
sion to chest wall or skin). The clinical characteristics of
the patients are summarized in Additional file 1: Table S1.
Tumor tissues were fixed in 4% neutral–buffered formal-
dehyde solution (pH 7.0) and were routinely processed for
paraffin embedding. Sections of 4 μm were used for im-
munohistochemistry staining.
Immunohistochemistry (IHC)
Paraffin-embedded sections were hydrated with serial
treatment with xylene and graded alcohols. Endogenous
peroxidase activity was blocked with 0.3% hydrogen per-
oxide for 60 min. Antigen retrieval was carried out by
heating at 95°C in 2 × 10−2 M citrate buffer (pH 6.0) or
10−3 M EDTA buffer (PH 8.0) for 20 min. After blocking
with horse serum (1:100), sections were incubated with
primary antibody (Additional file 1: Table S2) diluted
with PBS to various concentrations at 4°C overnight,
followed by washing in PBS. Antibody reactions were
colorized with the Dako REAL™ EnVision™ Detection
System (Dako, Glostrup, Denmark). Sections were coun-
terstained with Mayer’s hematoxylin. Positive and nega-
tive (primary antibody replaced by PBS) controls were
included for all staining procedures.
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Immunohistochemistry (IHC) staining was evaluated in-
dependently by two pathologists blinded from the clin-
ical data. Bmi1, cyclin D1 and pRB generally showed
nuclear staining in a diffuse pattern, and a negative reac-
tion was defined as absence of staining or occasional
positive cells which were less than 5% of the total tumor
cells. ERα and PR were scored as positive if at least 1%
of tumor cell nuclei were positive [23], but in our collec-
tion of specimens, a positive reaction typically had more
than 20% positive cells. HER2 was scored by accepted
criteria where intensity and completeness of membrane
staining were evaluated as previously described [24].
Ki-67 values were calculated as the percent of positively
stained cells in at least three randomly selected high
power fields (× 40 objective) [25]. The aberrant expression
of p16INK4a (+) in cancer cells was defined by cytoplasmic
staining with or without nuclear staining, distributed
either multifocally (10%-49% of cancer cells) or diffusely
(≥ 50% cells). Negative staining (―) was defined as no
staining in any cells, or no more than only occasional
positive cells (less than 5%). The subtypes in immu-
nohistochemistry were classified according to the refer-
ence and the cutoff of Ki-67 for determination of
Luminal-A or -B is 14% [1].
Statistical analysis
All data were analyzed with SPSS statistical software
(Version 13.0, Chicago, IL, USA). Relationships between
tumor markers and other parameters were analyzed
using the χ2-test, Pearson Chi-square test, Fisher’s exact
test or Student’s t test. P-values of less than 0.05 were
considered to be statistically significant and tests were
two tailed.
Cell culture and treatment
Human breast carcinoma MCF-7 and MDA-MB-231 cell
lines were maintained in DMEM (GIBCO, Carlsbad, CA,
USA) supplemented with 10% FBS (HyClone, Logan, UT)
at 37°C. For steroid treatment, cells were first cultured in
phenol-free DMEM (GIBCO) containing 10% double
charcoal-stripped FBS (Bioind, Kibbutz Beit Haemek,
Israel) for 72 h and then incubated with 10−8 M 17
β-estradiol (E2) (Sigma, St Louis, MO, USA) or 10−6 M 4-
Hydroxytamoxifen (4-OHT) (Sigma) dissolved in ethanol,
or with ethanol only (as a vehicle control) for indicated
lengths of time.
Western blot
Total protein samples from cell lysates were resolved on
SDS-polyacrylamide gels of different concentrations and
transferred onto nitrocellulose membranes (Amersham
Pharmacia Biotech, Uppsala, Sweden). After blocking with
5% nonfat milk for 60 min, membranes were incubatedwith appropriate primary antibodies (Additional file 1:
Table S2) at 4°C overnight, followed by incubation with
alkaline phosphatase-conjugated secondary antibody, and
were visualized using NBT/BCIP (Promega, Madison, WI,
USA). Densitometry was performed with Image J (1.42q
Software, NIH Public Domain).
Plasmids and transfection
Human Bmi1 [GenBank: NM_005180] was amplified with
primers 5′-GCAGATCTATGCATCGAACAACGAG-3′
(forward) and 5′-GCGTCGACTCAACCAGAAGAAGT
TG-3′ (reverse). Total RNA was isolated from cells with
Trizol reagent according to the manufacture’s protocol
(Invitrogen, Carlsbad, CA, USA) and was reversely tran-
scribed into cDNA with AMV reverse transcriptase
(Promega). The PCR product was digested with appropri-
ate restriction enzymes and subcloned into multiple clon-
ing sites of the pcDNA3.1/HisC vector (Invitrogen) and
sequenced, generating pcD-Bmi1. The pcDNA3.1-ERα
expression plasmid was a gift from Dr. Yongfeng Shang.
By using Lipofectamine 2000 reagent (Invitrogen),
MCF-7 cells were transiently transfected with pcD-Bmi1.
MDA-MB-231 cells were transfected with pcDNA3.1-ERα
(or empty vector) following the manufacture’s instruction
and selected in G418 (0.6 mg/ml). The stable clones which
were generated were designated as 231/ERα and 231/vec,
respectively.
Gene silencing with small interfering RNAs (siRNAs)
Three pairs of double-stranded siRNAs were synthesized
(GenePharma, Shanghai, China) based on the ERα mRNA







4 × 105 cells in 6-well plates were transiently transfected
with 100 pmol ERα siRNA using Lipofectamine 2000
reagent following the manufacture’s instruction. These
experiments were carried out independently three times.
Real time RT-PCR
Total RNA was isolated from cells with Trizol reagent ac-
cording to the manufacture’s protocol (Invitrogen, Carlsbad,
CA, USA) and was reversely transcribed into cDNA with
AMV reverse transcriptase (Promega). Real-time PCR was
set up with the Stratagene Mx3000p (Agilent Technologies,
Santa Clara, CA, USA) by using Brilliant® II SYBR Green
QPCR Master Mix (Agilent Technologies). PCR was per-
formed at 95°C for 15 s and 60°C for 60 s for 40 cycles. Pri-
mer sequences were as follows: ERα, 5′-TGCCCACTAC
TCTGGAGAAC-3′(forward) and 5′-CCATAGCCATACT
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AGTC-3′(reverse). The β-actin from the same extracts was
used as an internal control. The amount of ERα, Bmi1 and
p16INK4a were normalized to the β-actin value. Data were
calculated from the mean of three experiments.
Reporter construction and luciferase assay
Genomic DNA was prepared using standard molecular
techniques and was used as a template for amplifica-
tion of the Bmi1 promoter [GenBank: NC_000010.
10.3] with three different pairs of primers as follows:
region 1 (−1158 ~ +36) sense sequence 5′-CTTCAG
CTGAACCACCGTTTGTG-3′ and antisense sequence
5′-GCCAAGCTTCTGCCTCTCATACTACG-3′; region
2 (−850 ~ +36) sense sequence 5′-GTTCAGCTGCTAG
ATAGGAGTAGTGTG-3′ and antisense sequence 5′-
GCCAAGCTTCTGCCTCTCATACTACG-3′; region 3
(−203 ~ +36) sense sequence 5′-GTTCAGCTGCCCT
TAAGGAATGAGG-3′ and antisense sequence 5′-GCC
AAGCTTCTGCCTCTCATACTACG-3′; and region 4
(−116 ~ +36) sense sequence 5′-GTTCAGCTGTCAGT
TTCCACTCTG-3′ and antisense sequence 5′-GCCAAG
CTTCTGCCTCTCATACTACG-3′. PCR products were
digested with appropriate restriction enzymes and sub-
cloned into multiple SmaI-Hind III cloning sites on the
pGL2-Basic plasmid (Promega) and sequenced, generating
pGL2-1200, pGL2-900, pGL2-460, pGL2-240 and pGL2-
152 (Figure 1B).
Transfection was performed in 24-well plates (1 × 105
cells/per well) using Lipofectamine 2000 reagent with
200 ng of reporter (or pGL2-basic) and 2 ng of pRL-SV-
Renilla reference vector (Promega). Alternatively, in some
experiments 200 ng pcDNA3.1-ERα with 200 ng of
reporter (or pGL2-basic) and 2 ng of pRL-SV-Renilla
reference vector were co-transfected. Protein lysates
were prepared from post-transfected cells, and lucifer-
ase activities were measured with the Dual-Luciferase
Reporter Assay System (Promega) using a MicroBeta
TriLux Liquid Scintillation and Luminescence Counter
(Perkin-Elmer, Waltham, MA, USA). Firefly luciferase
activity was normalized to Renilla luciferase activity
and presented as a ratio (relative luciferase activity). All
experiments were performed independently at least
three times.
Chromatin immunoprecipitation (ChIP)
MCF-7, MDA-MB-231 and 231/ERα cells were held in
steroid starvation for 3 days and then treated with 10−8 M
E2 or vehicle (12 h) at 80% confluence. ChIP wasperformed as previously described [26]. Briefly, 5 × 106
cells per ChIP assay were cross-linked with 1% formalde-
hyde for 10 min at 37°C and then quenched with 125 mM
glycine. Cells were washed with cold PBS and scraped into
PBS with protease inhibitors (Roche, Indianapolis, IN,
USA). Cell pellets were resuspended in ChIP lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris–HCl. pH 8.1) and
sonicated with an Ultrasonic Homogenizer (Cole-Parmer,
Chicago, IL, USA) to produce sheared chromatin with
an average length of 500 bp. The sheared chromatin
was subjected to a clarification spin and the supernatant
was then used for ChIP or reserved for analysis of
“Input”. Anti-ERα antibody (Epitomics) was used and
normal rabbit IgG (Sigma) was used as negative control.
Primers for the ChIP-PCR assay were as follows: ChIP
primers (−327 ~ −172) for sense: 5′-CGTGTGGCGCT
GTGGAGAAATGTCT-3′ and antisense: 5′-GGGTC
ACGTGCTCCCCTCATTCCTT-3′; ChIP negative con-
trol primers (−2647 ~ −2523) sense: 5′-GTGGAAAG
TAGAGCCATTCT-3′ and antisense: 5′-AAACATCCG
TTATATGAGGG-3′.
Results
The expression of Bmi1 strongly correlated with ERα
status in breast cancer
Expression of Bmi1 was found in most non-neoplastic
tubular epithelial cells in breast tissue, and was also found
in a large proportion of breast cancer (79.35%, 73/92) by
immunohistochemistry (Figure 2). Positive staining for
Bmi1 was analyzed for comparison with other routine
markers of breast cancer including ERα, PR, HER2, and
Ki-67. The extent of positive staining for Bmi1 overlapping
ERα-positivity was striking (98.33%, 59/60), and this was
much less extensive overlap in the ERα-negative group
(43.75%, 14/32). Loss of Bmi1 expression was extraordi-
narily rare in the ERα-positive group (1.67%, 1/60) as
compared to the ERα-negative group (56.25%, 18/32).
Similarly, ERα positivity was found in 80.82% (59/73) of
the Bmi1 positive group and in 5.26% (1/19) of the Bmi1
negative group. These data indicate that the expression of
Bmi1 is positively correlated with estrogen receptor α sta-
tus (P < 0.0001) (Table 1). And expectedly, Bmi1 showed
similar rates of positivity in both Luminal-A (100.00%, 28/
28) and Luminal-B (96.15%, 25/26) (P = 0.481) (Table 2).
To further evaluate expression of Bmi1, its target gene
p16INK4a was analyzed in both Bmi1-positive and negative
groups with immunohistochemistry, and staining results
confirmed Bmi1 status (see ERα-coupled Bmi1 regulatory
signature in breast cancer in Results).
Since Bmi1 and ERα are both transcription regulators,
this marked overlap of expression suggested that Bmi1
and ERα could mutually regulate each other in a direct
way. At the same time, detailed analysis showed that the
rate of Bmi1 positivity in the ERα positive group was
Figure 1 (See legend on next page.)
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Figure 1 Effects of ERα on the transcriptional activity of Bmi1 promoter. (A) The composition of the Bmi1 core promoter. The transcription
element E-box is in italics, AP-1 is in boldface, several Sp-1 s are in the shadow box, and the putative ERα response elements (ERE) are underlined.
+1 indicates the transcription start. (B) Luciferase reporter construction. A series of reporters including pGL2-1200, pGL2-900, pGL2-460, pGL2-240
and pGL2-152 were constructed spanning the sequence +36 nt to −1158 nt of the Bmi1 promoter, and the two putative EREs were in black box.
(C) The transcriptional activity of the Bmi1 gene promoter in ERα-positive or –negative breast cancer cells. MCF-7 and MDA-MB-231 cells were
cultured in phenol red free medium containing 10% charcoal stripped FBS and transiently transfected with 200 ng each of empty pGL2-basic,
pGL2-1200, pGL2-900, pGL2-460. pGL2-240 or pGL2-152 in the absence or presence of 10−8 M E2, respectively. Cells were harvested 48 h after
transfection and assayed for luciferase activity. (D) The transfection of ERα enhanced transcriptional activity of the Bmi1 promoter. MCF-7 cells
were co-transfected with 200 ng each of reporter plasmids and 200 ng of ERα expression plasmid (pcDNA3.1-ERα) or pcDNA3.1 empty vector.
Cells were harvested 48 h after transfection and assayed for luciferase activity. (E) The reactivation of Bmi1 promoter in ERα-restored ERα-negative
cells. ERα-restored MDA-MB-231 cells (231/ERα) or their control 231/vec cells were transfected with 200 ng of each of the reporter plasmids.
The relative luciferase activity values are corrected for co-transfected Renilla activity. And the experiments were repeated at least three times
independently and all data are shown by bars as means ± SD (*P < 0.05, **P < 0.01, ***P < 0.001 when compared with the control
groups, respectively).
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tive rate of ERα in the Bmi1 positive group (80.82%,
59/73). In addition, in view of the fact that Bmi1 is a
transcription repressor, it seemed likely that ERα posi-
tively regulates the expression of Bmi1.
Taken together, these data suggested there is a correl-
ation between the expression of Bmi1 and ERα status and
raised the possibility that ERα affects Bmi1 expression.
ERα specifically regulates the expression of Bmi1 in
breast cancer cells
These data raised the possibility that ERα influences
Bmi1 expression, however, to rule out the possibility that
Bmi1 affects ERα expression, we repeatedly transiently
transfected MCF-7 cells with ectopic Bmi1, and con-
firmed that introduction of Bmi1 has no effect on the
expression of ERα (Figure 3A).
To determine whether Bmi1 is regulated by ERα, two
breast cancer cell lines, ERα-positive MCF-7 and ERα-
negative MDA-MB-231, were selected and treated with
10−8 M ERα ligand E2. In the presence of E2 (10−8 M), the
expression of Bmi1 in MCF-7 cells was enhanced in a time-
dependent manner, peaking at 12 h and persisting for at
least 36 h. At the same time, the level of p16INK4a declined
over a time course similar to that of Bmi1 (Figure 3B).
Conversely, the expression of Bmi1 in ERα negative MDA-
MB-231 cells showed no significant response to the
addition of 10−8 M E2 (Figure 3C). Moreover, the E2-
stimulated expression of Bmi1 and consequent sup-
pression of p16INK4a in MCF-7 cells was antagonized by
the antagonist OHT at 10−6 M (Figure 3D).
To further evaluate stimulation of Bmi1 expression by
ERα, ectopic ERα (pcDNA3.1-ERα) was stably introduced
into the ERα-negative MDA-MB-231 cells (Figure 4A). As
a result, the ERα-restored MDA-MB-231 cells (231/ERα)
displayed elevation of Bmi1 expression in a time dependent
manner in the presence of 10−8 M E2 (Figure 4B),
which was also inhibited by the addition of 10−6 M
OHT (Figure 4C). Conversely, the expression of Bmi1 inERα negative 231/vec cells showed no significant response
to the addition of 10−8 M E2 (Figure 4D) and 10−6 M
OHT (Figure 4E).
Taking another approach, three pairs of siRNAs against
different sequences of ERα were synthesized and tran-
siently transfected into MCF-7 cells, and after 72 h the ef-
fect of ERα silencing was confirmed by western blot. The
level of ERα protein was markedly reduced by siRNA3
(Figure 5A). ERα depleted MCF-7 cells showed a decrease
in expression of Bmi1, but expression of p16INK4a increased
as compared to the controls (NS group) (Figure 5B).
In summary, these results implied that ERα may spe-
cifically stimulate the functional expression of Bmi1.
ERα up-regulated Bmi1 expression at the transcription level
As a classic steroid hormonal receptor, ERα generally
regulates its target genes at the transcriptional level. The
sequences of the Bmi1 promoter were therefore re-
trieved and bio-informatically analyzed. The Bmi1 pro-
moter contains a series of GC-rich sequences close to its
transcription start site, and several putative transcription
factor elements including AP-1 (activator protein-1) and
Sp-1 (specificity protein-1) in addition to one confirmed
E-box (enhancer-box) [13,27,28], in which two putative
half estrogen responsive elements (ERE) were found to
overlap with the AP-1 and Sp-1 elements (Figure 1A).
Various regions which encompassed the Bmi1 up-stream
sequences according to the database sequences were
amplified and a series of luciferase reporters were gener-
ated, including pGL2-1200, pGL2-900, pGL2-460, pGL2-
240 and pGL2-152 (Figure 1B).
With a dual reporter system, MCF-7 and MDA-MB-
231 cells were transiently transfected with pGL2-1200,
pGL2-900, pGL2-460, pGL2-240 or pGL2-152 together
with a pRL-SV-Renilla luciferase reference vector. As ex-
pected, MCF-7 and MDA-MB-231 cells showed signifi-
cantly different reporter activities (Figure 1C). With
treatment of E2 (10−8 M), the reporter activity of the
Bmi1 promoter constructs was slightly increased in
Figure 2 (See legend on next page.)
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Figure 2 Expression of ERα, Bmi1, p16INK4a, PR, cyclin D1, pRB and Ki-67 in breast carcinoma. The left column: the representative images
for staining of ERα, Bmi1, p16INK4a, PR, cyclin D1, pRB and Ki-67 in non-cancerous breast tissue. The middle column: the representative images for
ERα positive breast cancer with Bmi1 positive and p16INK4a negative. The various positive staining of PR, cyclin D1, pRB and low Ki-67 index are
presented. The right column was representative images for ERα negative breast cancer with negative Bmi1 but diffuse staining of p16INK4a. The
various staining of PR, cyclin D1, pRB and high Ki-67 index are presented, respectively. (Hematoxylin /DAB, × 400).
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ever, upon co-transfection of the luciferase reporters
with pcDNA3.1-ERα into MCF-7 cells, there was an over-
all increase in transcription activity of the Bmi1 promoter
(Figure 1D). In order to observe the specificity of the effect
of ERα, the Bmi1 promoter reporters were transfected
into ERα-restored MDA-MB-231 cells (231/ERα), and
showed increased transcription activity as compared to
empty vector-transfected MDA-MB-231 cells (231/vec)
(Figure 1E). These results proved that ERα could activate
the transcription activity of the Bmi1 core promoter.
We further tested for ERα binding on the Bmi1 pro-
moter in MCF-7, MDA-MB-231 and 231/ERα cell lines
with ChIP. Following treatment of the cells with 10−8 M
E2, DNA immunoprecipitated with anti-ERα antibody
was amplified using Bmi1 promoter primers to eva-
luate the interaction of ERα with the Bmi1 promoter
at −327 ~ −172 bp (Figure 6). Results confirmed that
ERα can interact with the up-stream element of the
Bmi1 promoter.
ERα-coupled Bmi1 regulatory pathway in breast cancer
To evaluate the functional role of the ERα-coupled Bmi1
regulatory pathway in breast cancer, the expression ofTable 1 The correlation of Bmi1 or p16INK4a expression
with other commonly used markers of breast cancer
Bmi1 P value p16INK4a P value
– + – +
ERα <0.0001 <0.0001
– 18 14 9 23
+ 1 59 56 4
PR <0.0001 <0.0001
– 17 16 11 22
+ 2 57 54 5
Ki-67 <0.0001 <0.0001
0–13% 3 35 33 5
14–29% 1 15 15 1
30–49% 4 14 11 7
50–100% 11 9 6 14
Bmi1 – <0.0001
– – – 1 18
+ – – 64 9
Bold face representing significant data (P<0.05).p16INK4a or cyclin D1 which are target genes of Bmi1 and
ERα [29] respectively, was measured and their correlation
with other indices of breast cancer was analyzed.Down-regulation of ERα and Bmi1 correlated with aberrant
expression of p16INK4a
In normal tissues adjacent to breast cancer, p16INK4a was
expressed only in nuclei of occasional cells (Figure 2),
while p16INK4a showed aberrant staining of tumor cells
in 29.35% (27/92) of breast cancers, and this positive
staining was generally present in both the nuclei and
cytoplasm (Figure 2). Even in some cases, staining was
present mainly in the cytoplasm with decreased or ab-
sent nuclear staining. Aberrant staining for p16INK4a was
found in 71.88% (23/32) of ERα negative cases out of a
total of 92 cases of invasive carcinoma, compared to
ERα positive tumors (6.67%, 4/60). Similarly, p16INK4a
was frequently expressed in progesterone receptor (PR)
negative tumors (66.67%, 22/33) and was positive in only
a small number of cases in the PR positive group (8.47%,
5/59). p16INK4a expression showed a strong inverse cor-
relation with ERα and PR expression status (P < 0.0001,
P < 0.0001) (Table 1), indicating that aberrant expression
of p16INK4a is associated with loss of hormone receptors.
Similarly, Bmi1 was positive in most of the p16INK4a
negative group (98.46%, 64/65), while Bmi1 negativity
was found frequently with aberrant staining of p16INK4a
(66.76%, 18/27). There was a significant negative correl-
ation of Bmi1 with p16INK4a (P < 0.0001) (Table 1), dem-
onstrating aberrant expression of p16INK4a is associated
with reduced Bmi1 expression.Table 2 The aberrant expression of p16INK4a or Bmi1 in
molecular subtypes of breast cancer
Subtypes p16INK4a P value Bmi1 P value
- + - +
LA 28 0 <0.0001 0 28 <0.0001
LB 22 4 1 25
LHP 8 0 0 8
HP 5 11 7 9
TNBC 2 12 11 3
Total 65 27 19 73
Abbreviations: LA Luminal-A, LB Luminal-B, LHP Luminal-HER2-Positive,
HP HER2-Positive (HER2-enriched), TNBC Triple Negative Breast Cancer.
Bold face representing significant data (P<0.05).
Figure 3 Expression of Bmi1 was stimulated by E2 in ERα-positive breast cancer cells. (A) Effect of Bmi1 ectopic expression on ERα protein
in MCF-7 cells. MCF-7 cells were transiently transfected with Bmi1 (pcD-Bmi1), an empty vector, or transfection reagent (control). Cells were
collected after 48 h of transfection and analyzed for Bmi1, ERα and β-actin expression with Western blot. This image represents one of three
experiments. (B-D) Expression of Bmi1 was stimulated by E2 in ERα-positive breast cancer cells. ERα-positive MCF-7 (B) and ERα-negative MDA-MB-231
(C) cell lines were cultured in phenol red free medium containing 10% charcoal striped FBS for 72 h and 10−8 M E2 was added. At indicated time
points, cells were collected and analyzed for Bmi1, ERα, p16INK4a and β-actin expression by Western blot and real time RT-PCR (B’, right panel).
(D)MCF-7 cells were treated with 10−6 M OHT in the presence of E2 and Western blot was performed. β-actin was used as loading control. Quantitative
analyses of ERα, Bmi1 and p16INK4a are presented. All data were obtained from three independent experiments and are shown by bars as means ± SD
(*,# or △P < 0.05, **,## or △△P < 0.01, ***,### or △△△P < 0.001 when ERα, Bmi1 and p16INK4a were compared with the control group, respectively).
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tions of loss of ERα-coupled Bmi1 inducing abnormal
p16INK4a expression, the relationships between aberrant
p16INK4a expression and other factors in breast cancer
such as HER2 and Ki-67 were analyzed. p16INK4a ex-
pression was found in a majority of triple-negativebreast carcinomas (TNBC) (85.71%, 12/14) and HER2-
enriched carcinomas (68.75%, 11/16), whereas it was
less frequent in Luminal-B type tumors (15.38%, 4/26)
and was not found in Luminal-A tumor (0.00%, 0/28)
or in Luminal-HER2-Positive tumors (0.00%, 0/8).
p16INK4a positivity in triple negative breast cancer and
Figure 4 Expression of Bmi1 was stimulated by E2 in ERα-restored breast cancer cells. (A) 231/ERα and 231/vec were generated by stable
transfection of MDA-MB-231 cells by ERα or empty vector, respectively. (B) 231/ERα and (D) 231/vec cells were stimulated with 10−8 M E2, and
10−6 M OHT was added at the same time, (C and E). At indicated time, cells were collected and analyzed for Bmi1, ERα and β-actin expression
by Western blot and real time RT-PCR (B’, right panel). β-actin was used as loading control. Quantitative analyses of ERα, Bmi1 and p16INK4a are
presented. All data were obtained from three independent experiments and are shown by bars as means ± SD (#P < 0.05 when Bmi1 was compared
with the control group).
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http://www.biomedcentral.com/1471-2407/14/122HER2-enriched subtypes showed a marked statistical
difference from tumors in the other three groups (P <
0.0001) (Table 2). This specific distribution of aberrant
p16INK4a expression over the various molecular sub-
types pointed strongly to a relationship with hormone
receptor status.
The Ki-67 index is a chief factor for distinguishing the
Luminal-A and Luminal-B subtypes, so the relationshipof p16INK4a and Ki-67 expression was analyzed. For this
purpose, cases were classified into four Ki-67 expression
index groups which included 0-13%, 14%-29%, 30%-49%
and 50-100%. The positivity rates of p16INK4a in these
four groups were 13.16% (5/38), 6.25% (1/16), 38.89%
(7/18) and 70.00% (14/20), respectively. This result dem-
onstrated strong correlation of aberrant expression of
p16INK4a with the Ki-67 index (P < 0.0001) (Table 1).
Figure 5 Depletion of ERα decreased the level of Bmi1 and its E2 response. (A) MCF-7 cells were transiently transfected with three sets of
siRNAs specific for ERα (siRNA1, siRNA2, siRNA3) or with a control smart pool siRNA (NS), and 72 h after transfection cells were analyzed by Western blot
(left panel). Quantitative analyses of ERα protein expression by the three siRNAs are presented (right panel). (B) MCF-7 cells were transiently transfected
with siRNA3, and Bmi1, ERα and p16INK4a were analyzed by Western blot (left panel) and real time RT-PCR (right panel). β-actin was used as loading
control. Quantitative analyses of ERα, Bmi1 and p16INK4a are presented (middle panel). Right panel: quantitative analyses on mRNA of ERα, Bmi1 and
p16INK4a. All data were obtained from three independent experiments and are shown by bars as means ± SD (**,## or △△P < 0.01, ***P < 0.001 when ERα,
Bmi1 and p16INK4a were compared with the NS group, respectively).
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http://www.biomedcentral.com/1471-2407/14/122Expressions of ERα and Bmi1 correlated with activated
cyclinD1
Since cyclin D1 is a target of ERα [30], its expression
was analyzed with respect to either ERα or Bmi1. Cyclin
D1 was also positive more frequently in the ERα positive
group (90.00%, 54/60) (Figure 2), as compared to the
ERα negative group (50.00%, 16/32). Similarly, positive
cyclin D1 was also found in most cases positive for Bmi1
(86.30%, 63/73), while only a few cases of cyclin D1 were
found in the Bmi1 negative group (36.84%, 7/19). These
results demonstrated a positive correlation between ERα,
or Bmi1 and cyclin D1 (P < 0.0001, P < 0.0001). In ad–
dition, results showed that cyclin D1 positive cases pre-
dominated in the p16INK4a-negative group (84.62%, 55/
65), as compared to 55.56% (15/27) of cases which were
p16INK4a-positive, showing an inverse correlation with ab-
errant expression of p16INK4a (P = 0.003) (Table 3).The aberrant expression of p16INK4a or activated cyclin D1
did not correlate with pRB status
Phosphorylated RB (pRB), which is the inactivated form
of the RB protein was analyzed, and there were no obvious
differences in positive p16INK4a staining in pRB negative
versus pRB positive tumors (16/62, 25.81%; 11/30, 36.67%)
(P= 0.284) (Table 3), indicating that p16INK4a expression
has no correlation with pRB expression in this system
(Figure 2).Although the positivity rate for pRB in cyclin D1 positive
cases (35.71%, 25/70) was a little higher than that in cyclin
D1 negative tumors (22.73%, 5/22), the difference between
pRB expression and the cyclin D1 status was not statis-
tically different (P = 0.257) (Table 3). In addition, pRB
showed similar rates of positivity in both ERα-positive
(30.00%, 18/60) and ERα-negative cases (37.50%, 12/32)
(P = 0.465).
These data showed that neither aberrant p16INK4a ex-
pression nor activated cyclin D1 correlated with pRB in
these breast cancers.
Taken together, these findings show the ERα-coupled
Bmi1 regulation pathway plays an important role in
regulation of the genes and biological behavior of breast
cancer. The expression of ERα usually increases both
levels of Bmi1 and cyclin D1, while loss of ERα-coupled
Bmi1 activity may result in aberrant p16INK4a expression
and is also generally consistent with a more aggressive
breast cancer phenotype.
Discussion
The role of Bmi1 and the related functional network that
serves in regulation of normal cells and cancer cells have
been studied extensively in recent years. However, regu-
lation of its expression, and especially the mechanism of
its up-regulation in cancers, has rarely been explored
[14,15]. To date, only E2F1 and MYCN have been shown
to be direct activators of Bmi1 transcription in some kinds
Table 3 Correlation of Cyclin D1 or pRB with ERα, Bmi1
and p16INK4a expression in breast cancer
Cyclin D1 P value pRB P
value– + – +
ERα <0.0001 0.465
– 16 16 20 12
+ 6 54 42 18
Bmi1 <0.0001 0.659
– 12 7 12 7
+ 10 63 50 23
p16INK4a 0.003 0.284
– 10 55 46 19
+ 12 15 16 11
CyclinD1 – 0.257
– – – 17 5
+ – – 45 25
Bold face representing significant data (P<0.05).
Figure 6 Interaction of ERα and Bmi1 promoter. MCF-7, MDA-MB-231 and 231/ERα treated or untreated with 10−8 M E2 for 12 h were used
for Chromatin immunoprecipitation (ChIP) analysis of the human Bmi1 promoter as described in Methods. ERα: anti-ERα antibody; IgG: rabbit IgG.
Bmi1 promoter: region (−327 bp to −172 bp), and control: region (−2647 bp to −2523 bp). PCR products were resolved on a 2% agarose gel.
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http://www.biomedcentral.com/1471-2407/14/122of cancers [31,32], and data regarding Bmi1 in tumor biol-
ogy are far from complete. The over-expression of Bmi1
and its 11-gene signature has been defined in breast car-
cinoma [18]. At the same time, investigation has shown
that Bmi1 expression is positively correlated with ERα sta-
tus in breast cancer [33-35]. However, the direct inter-
action between these molecules has not been evaluated.
ERα is extremely important in tumorigenesis in female
sex organs, and its signaling pathway has thus been ex-
tensively investigated [2,4]. As a classic nuclear receptor,
it translocates into the nucleus upon binding of estro-
gen to dimerized ERα, and brings about activation of
transcription of target genes via interaction with either
ERE (estrogen responsive element) or other factors such
as steroid receptor coactivator-1 (SRC-1), amplified in
breast 1 (AIB1, also known as NCOA3) and E1A binding
protein as well as p300/CREB binding protein (p300/CBP)
[6,36,37]. The Bmi1 promoter is a classic house-keeping
gene as it possesses such features as a non-TATA box, and
it has GC-rich sequences, putative AP-1 and Sp-1 ele-
ments, and a functional E-box, which has been identified
to interact with several transcription factors in regulation
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http://www.biomedcentral.com/1471-2407/14/122of cell proliferation, stress and senescence [13,27,28]. Our
experiments demonstrated that ERα can activate the tran-
scription of Bmi1 through directly interacting with its pro-
moter. However, it is noteworthy that the magnitude of
E2-inducing Bmi1 promoter activity appears to be much
lower than that of E2-inducing Bmi1 protein levels in
MCF7 cells. It is possible the Bmi1 promoter was weak in
transcriptional activity in this study, as only low reporter
activity was measured under basal conditions (Figure 1C).
On the other hand, our study also revealed that over-
expression of ERα markely stimulates transcription ac-
tivity of the Bmi1 promoter as compared to the addition
of E2 (Figure 1D, C). This may imply that the level of en-
dogenous ERα more effectively affects the Bmi1 promoter
than the concentration of cellular estrogen, which is con-
sistent with the correlation found in the ERα status and
the expression of Bmi1 in breast cancer. Although only
two putative ERE elements were found to be embedded in
the E-box and AP-1 consensus, it seemed that the up-
stream GC-rich sequences might be involved, since lucif-
erase reporters spanning the −425 region were responsive
to transfection of ERα. Such results are similar to those
which have been found in many ERα response genes, in
which the GC-box, AP-1, −2 or Sp-1 are involved in ERα
stimulation [36,37]. Despite the fact our investigation
revealed that Bmi1 expression is determined by ERα
status in breast cancer, it must be noted that nearly half of
the cases with loss of ERα still expressed Bmi1 or cyclin D1
which is another ERα target gene [29,38]. This suggested
the possibility that Bmi1 or cyclin D1 is induced mainly by
ERα. However if there is no expression of ERα, Bmi1 may
be induced by other factors such as E2F1 and MYC [31,32],
both of which are usually expressed in cancers.
p16INK4a-cyclinD1/RB consists of machinery for regu-
lation of cell cycle progression. Several observations
have suggested that inactivation of RB in the genome
or in the phenotype can lead to abnormal expression of
p16INK4a or cyclin D1, and promote cell cycle G1-S
transition, resulting in sensitivity to loss of inhibition by
ERα in cancer cells [39,40]. Therefore, the disruption of
p16INK4a-cyclinD1/RB is believed to be a mechanism of
resistance to endocrine therapy. However, our investiga-
tion showed that the expression of p16INK4a and cyclin D1
is largely dependent on the activity of the ERα-coupled
Bmi1 regulatory machinery, but not on RB status. In fact,
although a preliminary report implied that p16INK4a/RB is
abnormally expressed in breast cancer [33], recent studies
demonstrated that over-expression of p16INK4a is indica-
tive of a more undifferentiated malignant phenotype in
mammary carcinoma, such as the basal-like phenotype, in
which ERα is generally negative [34].
p16INK4a is a well known tumor suppressor and loss of
its activity has been found widely in many kinds of human
cancers [41]. However, its aberrant expression, in whichp16INK4a not only over-expresses but also changes its sub-
cellular distribution from nuclear to cytoplasmic, has also
been found in some types of cancer, especially in pre-
cancerous cervical lesions and cancers [42]. In fact the ab-
errant expression of p16INK4a has become a pathologic
indicator of high tumor grade in cervical precancerous
lesions [43]. As p16INK4a is a cyclin-dependent kinase
inhibitor which is closely related to RB status, the aber-
rant expression of p16INK4a is usually considered to be
the result of compensation for RB inactivation, which
occurs frequently in HPV-related cervical carcinogen-
esis [41,42]. Nevertheless, in this study we found a posi-
tive relationship between p16INK4a and Bmi1 instead of
RB. In fact, p16INK4a has long been understood to be a
target of Bmi1, and a recent study has shown multiple
Bmi1-interactive elements in the upstream of p16INK4a
[44]. These results indicate that in contrast to cervical
neoplasia, the disruption of the ERα-Bmi1 pathway is
most likely a primary cause of aberrant p16INK4a expres-
sion in breast cancer. In addition, aberrant expression
of p16INK4a may be a marker for ERα negative breast
cancers such as the TNBC and HER2-enriched sub-
types, and may also be useful in distinguishing HER2-
enriched from Luminal-B-HER2 positive breast tumors.
This study also demonstrates a positive relationship
between ERα-Bmi1 and cyclin D1 in ERα-positive breast
cancer. However, direct interaction exists only between
cyclin D1 and ERα rather than Bmi1, and the expression
of cyclin D1 in breast cancer probably reflects the regu-
latory effect of ERα. Therefore, the distribution of cyclin
D1 in the various tumor subtypes was consistently found
to be correlated with ERα status.
However, considering the heterogeneity of breast
cancer, the clinical cohort in this described research is
relatively modest. Therefore, further investigation is
necessary.
Nevertheless, more attention should be paid to the dis-
covery that ERα regulated expression of Bmi1, which
could be a challenge to the general opinion of Bmi1 for
its crucial role in regulating self-renewal of stem cells or
cancer stem cells [13-15]. However, in a comprehensive
analysis of Bmi1, Pietersen et al. also reveals a more in-
trinsic role of Bmi1 in development and homeostasis of
mammary glands [45]. They demonstrate that Bmi1 ex-
presses especially highly in luminal cells, which usually
express hormone receptors. And knock-out of Bmi1 affects
differentiation and proliferation of mammary stem cells
but not reduces their number. In addition, loss of Bmi1
can induce premature lobuloalveolar differentiation, in-
dicating that Bmi1 also affects more committed cells of
mammary gland [45]. Combining the data with our results,
we believe that there should be a close functional relation-
ship between ERα and Bmi1, which also be crucial in
regulation of breast cancers, especially in luminal-type
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http://www.biomedcentral.com/1471-2407/14/122carcinomas. Therefore, the exact role of ERα coupled Bmi1
pathway in breast cancer need to be further explored.
Conclusions
This investigation revealed a regulatory relation between
Bmi1 and ERα, and demonstrated an ERα-coupled Bmi1
signaling pathway in breast cancer. These results further
reinforced the critical nature of the role of ERα in the
development and treatment of breast cancer, and suc-
cessful identification and description of ERα associated
molecular events will provide a greater foundation for
prevention and therapy of breast cancer.
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